NEUROENDOCRINE CARCINOMAS (NEC)
Clinical trials for NEUROENDOCRINE CARCINOMAS (NEC) explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMAS (NEC) trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMAS (NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare, aggressive cancers: trial tests Immune-Boosting drug
Disease control Recruiting nowThis study is testing a new drug called tarlatamab for people with a rare and aggressive type of cancer called extrapulmonary neuroendocrine carcinoma (EPNEC). The cancer has returned or worsened after standard chemotherapy. The trial will see if tarlatamab, which works by direct…
Matched conditions: NEUROENDOCRINE CARCINOMAS (NEC)
Phase: PHASE2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat cancers: first human trial of experimental drug begins
Disease control Recruiting nowThis early-stage study is testing a new drug called PT217 for people with advanced neuroendocrine cancers that have spread or come back after standard treatments. Researchers will first find the safest dose of PT217 given alone, then test it combined with chemotherapy. The goal i…
Matched conditions: NEUROENDOCRINE CARCINOMAS (NEC)
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC